9 research outputs found
PHP148 Early Benefit Assessment (EBA) in Germany: Differences Between Pharmaceutical Companies' Claims and IQWiG Benefit Assessments
PNS266 DIFFERENT INTERPRETATION OF ADDITIONAL EVIDENCE FOR HTA BY THE COMMISSIONED HTA BODY AND THE COMMISSIONING DECISION MAKER IN GERMANY: WHENEVER IQWIG AND FEDERAL JOINT COMMITTEE DISAGREE
Multi-Dimensional Capture of Patient-Relevant Endpoints in Regulatory Trials and Health Technology Assessments in Oncology Two Years After Introduction of the German Amnog Health Care Reform
PSS24 How Do Glaucoma Patients Assess Different Aspects of Their Treatment: An Elicitation of Patients' Preferences Using the Analytic Hierarchy Process
PSY80 PRIORITIZATION AND WEIGHTING OF PATIENT-RELEVANT ENDPOINTS (PRES) AS PART OF THE IQWIGS EFFICIENCY FRONTIER METHOD IN GERMANY
PCN152 Patient-Relevant Endpoints (PRE) in Oncology - Current Issues in the Context of Early Benefit Assessment (EBA) in Germany: An Industry Perspective
Health Care Use and Costs in Individuals With Diabetes With and Without Comorbid Depression in Germany: Results of the Cross-sectional DiaDec Study
OBJECTIVE Increased health care use and costs have been reported in individuals with diabetes with comorbid depression. Knowledge regarding cost differences between individuals with diabetes alone and those with diabetes and diagnosed/undiagnosed depression is, however, scarce. We therefore compared use and costs for patients with diabetes and no depression and patients with diabetes and documented depression diagnosis or self-reported depression symptoms for several cost components, including mental health care costs. RESEARCH DESIGN AND METHODS Data from a 2013 cross-sectional survey of randomly sampled members of a nationwide German statutory health insurance (SHI) provider with diabetes (n = 1,634) were linked individually with SHI data covering four quarters before and after the survey. Self-reported depression symptoms were assessed with the Patient Health Questionnaire-9, with depression diagnosis taken from SHI data. We analyzed health care use and costs, using regression analysis to calculate cost ratios (CRs) with adjustment for sociodemographic/socioeconomic factors and comorbidities for two groups: 1) those with no symptoms and no diagnosis and 2) those with symptoms or diagnosis. In our explorative subanalysis we analyzed subgroups with either symptoms or diagnosis separately. RESULTS Annual mean total health care costs were higher for patients with comorbid depression (EUR 5,629 [95% CI 4,987-6,407]) than without (EUR 3,252 [2,976-3,675], the CR being 1.25 [1.14-1.36]). Regression analysis showed that excess costs were highly associated with comorbidities. Mental health care costs were very low for patients without depression (psychotherapy EUR 2; antidepressants EUR 4) and still relatively low for those with depression (psychotherapy EUR 111; antidepressants EUR 76). CONCLUSIONS Costs were significantly higher when comorbid depression was present either as symptoms or diagnosed. Excess costs for mental health services were rather low